Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study

Table 1 Differentiation of various groups of patients from each other, and from healthy controls with the identified miRNA pairs

Groups of subjects compared	Biomarker miRNA pairs	P-value
GI system diseases versus controls	miR-215/miR-30e-3p	2.60E-09
	miR-215/miR-145	6.30E-10
	miR-203/miR-30e-3p	1.80E-09
	miR-203/miR-145	1.20E-10
Pulmonary system diseases versus controls	miR-486-5p/miR-409-3p	4.10E-09
	miR-486-5p/miR-146-5p	1.70E-10
	miR-34b/miR-409-3p	2.20E-06
	miR-34b/miR-146-5p	7.40E-06
GI system diseases versus Pulmonary system diseases	miR-145/miR-155	7.60E-11
	miR-486-5p/miR-155	7.90E-11
	miR-145/miR-30e-3p	7.80E-06
	miR-192/miR-31	9.80E-06
Cancers versus Inflammatory diseases	miR-126/miR-30e-3p	9.90E-08
	miR-31/miR-155	8.30E-09
	miR-146b-5p/miR-30e-3p	1.77E-09
	miR-146b-5p/miR-155	5.86E-10

All P-values given in the table are highly statistically significant. The threshold for statistical significance, as calculated with the Bonferroni correction, is 1.8E-03 for “GI system diseases versus controls” and for “Pulmonary system diseases versus controls”; and 3.0E-04 for “GI system diseases versus Pulmonary system diseases” and for “Cancers versus Inflammatory diseases” (see Methods).

ISSN: 1479-5876